MLTX: MoonLake Immunotherapeutics Stock

by  •  • Comments Off on MLTX: MoonLake Immunotherapeutics Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,519.92
Enterprise Value ($M) 2,346.06
Book Value ($M) 453.39
Book Value / Share 7.16
Price / Book 5.56
NCAV ($M) 449.75
NCAV / Share 7.11
Price / NCAV 5.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.23
Return on Equity (ROE) -0.23

Liquidity (mrq)
Quick Ratio 21.11
Current Ratio 21.11

Balance Sheet (mrq) ($M)
Current Assets 474.29
Assets 477.93
Liabilities 24.54
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -143.09
Net Income -118.94

Cash Flow Statement (mra) ($M)
Cash From Operations -116.59
Cash from Investing -205.60
Cash from Financing 51.31

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Price T Rowe Associates Inc /md/ 5.30 306.47
02-12 13G/A Fmr Llc 10.00 27.63
10-08 13D/A Biotechnology Value Fund L P 31.40 -9.19
2024-02-14 13G/A Chen Bihua 14.17 23.24
2024-02-14 13G/A Citadel Advisors Llc 3.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-05-07 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 35,097 295,295 11.89
2025-03-06 33,407 119,899 27.86
2025-03-05 20,657 192,959 10.71
2025-03-04 54,941 203,800 26.96

(click for more detail)

Similar Companies
ME – 23andMe Holding Co. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc. MNPR – Monopar Therapeutics Inc.
MRKR – Marker Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io